5th COST Harmonis@tion Adrenal Tumor Masterclass

5^th COST Harmonis@tion Adrenal Tumor Masterclass

For more information contact goharmonisation@gmail.com

Programme

Chairs: Martin Fassnacht, Anja Barac Nekic

April 15th, 2024

4.30 p.m.

Barbara Altieri

Managing mitotane treatment in ACC with a focus on adverse effects.

5.00 p.m.

Christina Pamporaki

Are there any tools on the horizon to replace the ARR for screening for PA?

5.30 p.m.

Gauthier Chassang

Ethical and regulatory aspects in sharing clinical data (and samples) for research between EU countries.

6.00 p.m.

Rodrigo Toledo & Cristina Ronchi

Liquid biopsy in adrenal tumors - which method to use and when?

Chairs: Dimitra Vassiliadi, Antoan Stefan Sojat

16th April, 2024

4.30 p.m.

Alessandro Prete

How reliable are the results of a single 1mg dexamethasone test in patients with adrenal incidentalomas?

5.00 p.m.

Tracy Williams

Debulking surgery for PA: is a fundamental dogma in the management of PA falling?

5.30 p.m.

Guillaume Assie

ENSAT registry. Legal and ethical considerations.

6.00 p.m.

Eric Baudin

Malignant PPGL - how does FIRST-MAPPP change the treatment landscape?

Follow Harmonisation

COST

COST is an EU funding programme that enables researchers to set up their interdisciplinary research networks in Europe and beyond. We provide funds for organising conferences, meetings, training schools, short scientific exchanges or other networking activities in a wide range of scientific topics. By creating open spaces where people and ideas can grow, we unlock the full potential of science.

HARMONIS@TION

Harmonis@tion aims to constitute a multidisciplinary network to harmonize clinical care and research on adrenal tumours throughout Europe with a focus on COST Inclusiveness Target Countries. In addition, this collaborative network will establish a modern framework to develop a new generation of real-time and real-life randomized clinical trials, which will be federated and registry-based.

Action Details

Start of Action: 28/09/2021

End of Action: 27/09/2025

Our Partners